Department of Breast Surgery, The First Hospital of Jilin University, Changchun, Jilin 130012, P.R. China.
Int J Oncol. 2022 Aug;61(2). doi: 10.3892/ijo.2022.5385. Epub 2022 Jun 28.
Triple‑negative breast cancer (TNBC) is a highly heterogeneous and aggressive malignancy. Due to the absence of estrogen receptors and progesterone receptors and the lack of overexpression of human epidermal growth factor receptor 2, TNBC responds poorly to endocrine and targeted therapies. As a neoadjuvant therapy, chemotherapy is usually the only option for TNBC; however, chemotherapy may induce tumor resistance. The emergence of immunotherapy as an adjuvant therapy is expected to make up for the deficiency of chemotherapy. Most of the research on immunotherapies has been performed on advanced metastatic TNBC, which has provided significant clinical benefits. In the present review, possible immunotherapy targets and ongoing immunotherapy strategies were discussed. In addition, progress in research on immune checkpoint inhibitors in early TNBC was outlined.
三阴性乳腺癌（TNBC）是一种高度异质性和侵袭性的恶性肿瘤。由于缺乏雌激素受体和孕激素受体，以及人表皮生长因子受体 2 的过度表达，TNBC 对内分泌治疗和靶向治疗反应不佳。作为新辅助治疗，化疗通常是 TNBC 的唯一选择；然而，化疗可能会诱导肿瘤耐药。免疫疗法作为辅助疗法的出现有望弥补化疗的不足。大多数免疫疗法的研究都集中在晚期转移性 TNBC 上，这为临床带来了显著的获益。在本综述中，讨论了可能的免疫治疗靶点和正在进行的免疫治疗策略。此外，还概述了免疫检查点抑制剂在早期 TNBC 研究中的进展。
